Healthcare Technology Featured Article

April 24, 2013

MMRGlobal Receives NOA for Anti-CD20 Used to Treat Cancer


The Australian Patent Office issued a Notice of Allowance (NOA) to MMRGlobal Inc, for the company’s anti-CD20 monoclonal antibody assets. This antidote can be used as a way for patients to fight cancer and other diseases.

Anti-CD20 (also known as Rituximab) is a non-glycosylated phosphoprotein expressed on the surface of all mature B-cells and has been approved in various countries as a treatment of B-cell lymphoma. The antibody is currently being used in an experimental capacity for other immune-related diseases such as immune thrombocytopenic purpura, systemic lupus, and transplant recipients.

MMRGlobal has been experimenting with the antibody, known in the company as #2007338607, Antibodies and Methods for Making and Using Them. The company applied for a patent back in 2007 and was finally awarded its NOA this week.

According to a press release from MMRGlobal, sales of anti-CD20 have reached a record high of more than $7 billion in 2012.

MMRGlobal is not stopping there; the company is investing in a bunch of health-related technology companies such as U.S. Health Information Technology (HIT). This company is also working on delivering personal health records electronically.

"Since the inception of MMR in 2005, the Company has incurred more than 40 million dollars in expenses to get our HIT products and services and related IP to where it is today. I am optimistic as I watch consumers and employers finally understand and embrace the importance of having a Personal Health Record,” said Robert H. Lorsch, MMRGlobal CEO.

He added, “This is evidenced by activity everywhere, including the current Public Voting Campaign in New York and similar programs which we believe also may infringe on the company's intellectual property. We're finally seeing the acceptance of health IT products and services such as personal health records and patient portals in a market being driven globally by government regulations and usage mandates.”

MMRGlobal plans on continuing to invest in anti-CD20, vaccine trials, experimental treatments and other patents in the near future.




Edited by Jamie Epstein
Get stories like this delivered straight to your inbox. [Free eNews Subscription]




SHARE THIS ARTICLE



FREE eNewsletter

Click here to receive your targeted Healthcare Technology Community eNewsletter.
[Subscribe Now]